Press
Releases

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 25, 2019 – Liminal BioSciences Inc. (TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage small molecules company...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 24, 2019 – Liminal BioSciences Inc. (TSX: LMNL) (“Liminal BioSciences”), a biopharmaceutical company focused on developing novel...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 18, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences" or the "Company"), a clinical-stage small molecules...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 3rd, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) ("Prometic" or the "Company"), a biopharmaceutical company focused on...

Novel, orally active immuno-metabolic agent Potential therapy for NAFLD/NASH, metabolic syndrome and other liver diseases Fully owned and proprietary to Prometic LAVAL, CANADA, ROCKVILLE, USA and...

LAVAL, CANADA, ROCKVILLE, USA and CAMBRIDGE, UK – September 4, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel...

LAVAL, QUEBEC, CANADA, ROCKVILLE, MD, USA and CAMBRIDGE, UK – September 3, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) ("Prometic" or the "Company"), a biopharmaceutical...

C$229 (US 173) million of outstanding debt converted into Common Shares C$114 (US$87) million in gross proceeds raised in concurrent financings Internal promotions within the management team for...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – August 8th, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCD) (Prometic), wishes to correct an error in its press release entitled...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – August 7th, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel...